MYD88 and neoplasm: In untreated mice, we found moderately improved outcomes in both Itgax-Cre/Myd88fl/fl and Lyz2-Cre/Myd88fl/fl mice, implicating MyD88 as an immunosuppressive factor in both DCs and myeloid cells during tumor growth (Fig. 2A).